Ketamine is an underutilized and lesser known psychedelic for practitioners looking to participate in the much anticipated revolution and legalization of psychedelic-assisted therapy. However, it is a current legal tool that can help practitioners prepare for the coming psilocybin and MDMA assisted therapy, as well as provide relief to clients/patients with treatment-resistant mental conditions.
Ketamine, a swiftly acting synthetic compound, has served as an anesthetic and pain management solution for over five decades. Acting upon the N-methyl-D-aspartate (NMDA) receptor within the central nervous system, it plays a pivotal role in the extensive glutamate pathway responsible for excitatory signals. Notably, medical research highlights ketamine’s efficacy in addressing treatment-resistant depression, offering hope for those with recalcitrant suicidality and other persistent mental health issues. When employed at doses lower than those for anesthesia, ketamine, in conjunction with structured psychotherapy, can induce profound dissociative, transcendent, or psychedelic experiences. This presents a potentially valuable avenue for mental wellness.
Ketamine Assisted Therapy (KAT) aka Ketamine Assisted Psychotherapy (KAP) is an evolving field of practice. This is due to emerging evidence that KAP, where ketamine complements talk therapy, holds promise for a range of mental health conditions. This includes depression, post-traumatic stress disorder, obsessive-compulsive disorder, and substance use disorders. As research and real life treatment results continue to show high effectiveness, the landscape of Ketamine Assisted Therapy is poised to expand, offering new avenues for mental health care.
Join us, along with Cena Life KAP clinic and KAP therapist Patrizia Giampaolo, for a live info session with Q&A to discuss KAP and how you can begin offering it to your patients/clients.
What we will discuss:
Join our newsletter for the latest updates, insights, and exclusive offers on everything psychedelic therapy.